Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor

Yoon, Hyun Joong; Chung, Yong Eun; Lee, Yong Jae; Yu, Seung Eun; Baek, Seung Wook; Kim, Hye Seon; Kim, Sang Wun; Lee, Jung‐Yun; Kim, Sung Hoon; Sung, Hak‐Joon

doi:10.1002/advs.202102640

Cited by 5 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that organoids can reproduce the biological characteristics and tumor heterogeneity of primary tissues, making them a novel and reliable clinical model in the study of gynecological malignant tumors ( Sachs et al, 2018 ; Kopper et al, 2019 ; Yoon et al, 2021 ). Kopper et al established 56 organoid lineages from OC tissue and tested their sensitivity to commonly used platinum or paclitaxel drugs in OC treatment regimens.…”

Section: Introductionmentioning

confidence: 99%

Research progress on the application of organoids in gynecological tumors

Shen,

Wang,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Organoids are in vitro 3D models that maintain their own tissue structure and function. They largely overcome the limitations of traditional tumor models and have become a powerful research tool in the field of oncology in recent years. Gynecological malignancies are major diseases that seriously threaten the life and health of women and urgently require the establishment of models with a high degree of similarity to human tumors for clinical studies to formulate individualized treatments. Currently, organoids are widely studied in exploring the mechanisms of gynecological tumor development as a means of drug screening and individualized medicine. Ovarian, endometrial, and cervical cancers as common gynecological malignancies have high morbidity and mortality rates among other gynecological tumors. Therefore, this study reviews the application of modelling, drug efficacy assessment, and drug response prediction for ovarian, endometrial, and cervical cancers, thereby clarifying the mechanisms of tumorigenesis and development, and providing precise treatment options for gynecological oncology patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Research progress on the application of organoids in gynecological tumors

Shen,

Wang,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Tissue Niche Miniature of Glioblastoma Patient Treated with Nano‐Awakeners to Induce Suicide of Cancer Stem Cells

Yoon

Baek

et al. 2022

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Patient-specific cancer therapies can evolve by vitalizing the mother tissue-like cancer niche, cellular profile, genetic signature, and drug responsiveness. This evolution has enabled the elucidation of a key mechanism along with development of the mechanism-driven therapy. After surgical treatment, glioblastoma (GBM) patients require prompt therapy within 14 days in a patient-specific manner. Hence, this study approaches direct culture of GBM patient tissue (1 mm diameter) in a microchannel network chip. Cancer vasculature-mimetic perfusion can support the preservation of the mother tissue-like characteristic signatures and microenvironment. When temozolomide and radiation are administered within 1 day, the responsiveness of the tissue in the chip reflected the clinical outcomes, thereby overcoming the time-consuming process of cell and organoid culture. When the tissue chip culture is continued, the intact GBM signature gets lost, and the outward migration of stem cells from the tissue origin increases, indicating a leaving-home effect on the family dismantle. Nanovesicle production using GBM stem cells enables self-chasing of the cells that escape the temozolomide effect owing to quiescence. The anti-PTPRZ1 peptide display and temozolomide loading to nanovesicles awakes cancer stem cells from the quiescent stage to death. This study suggests a GBM clinic-driven avatar platform and mechanism-learned nanotherapy for translation.

show abstract

Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor

et al. 2021

Self Cite

View full text Add to dashboard Cite

The current paradigm of cancer medicine focuses on patient-and/or cancer-specific treatments, which has led to continuous progress in the development of patient representatives (e.g., organoids) and cancer-targeting carriers for drug screening. As breakthrough concepts, i) living cancer tissues convey intact profiles of patient-specific microenvironmental signatures. ii) The growth mechanisms of cancer mass with intense cell-cell interactions can be harnessed to develop self-homing nano-targeting by using cancer cell-derived nanovesicles (CaNVs). Hence, a tissueoid model of ovarian cancer (OC) is developed by culturing OC patient tissues in a 3D gel chip, whose microchannel networks enable perfusion to maintain tissue viability. A novel model of systemic cancer responses is approached by xenografting OC tissueoids into ischaemic hindlimbs in nude mice. CaNVs are produced to carry general chemotherapeutics or new drugs under pre/clinical studies that target the BRCA mutation or energy metabolism, thereby increasing the test scope. This pioneer study cross-validates drug responses from the OC clinic, tissueoid, and animal model by demonstrating the alignment of results in drug type-specific efficiency, BRCA mutation-dependent drug efficiency, and metabolism inhibition-based anti-cancer effects. Hence, this study provides a directional foundation to accelerate the discovery of patient-specific drugs with CaNV application towards future precision medicine.

show abstract

Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor

Cited by 5 publications

References 60 publications

Research progress on the application of organoids in gynecological tumors

Research progress on the application of organoids in gynecological tumors

Tissue Niche Miniature of Glioblastoma Patient Treated with Nano‐Awakeners to Induce Suicide of Cancer Stem Cells

Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor

Contact Info

Product

Resources

About